跳至主要内容
临床试验/CTRI/2018/06/014584
CTRI/2018/06/014584
已完成
未知

Clinical efficacy of intralesional platelet rich plasma therapy in melasma - PRP therapy

Department of Dermatology0 个研究点目标入组 40 人待定

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
未指定
发起方
Department of Dermatology
入组人数
40
状态
已完成
最后更新
4年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
2019年8月30日
最后更新
4年前
研究类型
Interventional

研究者

入排标准

入选标准

  • 1\.Patients with clinical diagnosis of melasma

排除标准

  • 1\. Patients with known platelet dysfunction syndrome, critical thrombocytopenia ( \<50,000/ul), any hemodynamic instability or with hemoglobin level \< 10 g/dl.
  • 2\. Patients with local inflammatory skin disorders or active herpes infection at the site of the procedure.
  • 3\. Patients with corticosteroid injection at treatment site within 1 month or systemic use of corticosteroids within 2 weeks.
  • 4\. Patients diagnosed with cancer especially hematopoietic or of bone.
  • 5\. Patient with known hypersensitivity to platelet rich plasma or any other form of blood components.
  • 6\. Patients with any other facial dermatoses.
  • 7\. Patients on anticoagulants, oral contraceptive pills, hormone replacement therapy, NSAIDs, antiepileptic medications, isotretinoin or any other phototoxic medication.
  • 8\. Pregnancy and lactation.

结局指标

主要结局

未指定

相似试验